Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Camurati-Engelmann Syndrome × LY-2157299 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 3 Neoplasms 3 Carcinoma, Hepatocellular 3 Neoplasm Metastasis 2 Glioma 2 Glioblastoma 1 Carcinosarcoma 1 Camurati-Engelmann Syndrome 1

Interventions

bintrafusp alfa protein, human 2 Radiotherapy 2 fresolimumab 1 ascrinvacumab 1 Trabedersen 1 Temozolomide 1 Sorafenib 1 Paclitaxel 1 Lomustine 1 LY-2157299 1 Fenretinide 1 Drug Delivery Systems 1 Cisplatin 1 Carboplatin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02178358 2022-02-25

A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma

Eli Lilly and Company

Phase 2 Completed

132 enrolled 25 charts

Gastrointestinal

Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡